Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gain Therapeutics (GANX) Operating Expenses (2020 - 2025)

Historic Operating Expenses for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to $4.8 million.

  • Gain Therapeutics' Operating Expenses rose 732.93% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.6 million, marking a year-over-year decrease of 1797.26%. This contributed to the annual value of $20.4 million for FY2024, which is 877.57% down from last year.
  • Per Gain Therapeutics' latest filing, its Operating Expenses stood at $4.8 million for Q3 2025, which was up 732.93% from $5.1 million recorded in Q2 2025.
  • Gain Therapeutics' Operating Expenses' 5-year high stood at $8.2 million during Q2 2024, with a 5-year trough of $2.5 million in Q1 2021.
  • Over the past 5 years, Gain Therapeutics' median Operating Expenses value was $4.6 million (recorded in 2022), while the average stood at $4.7 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first soared by 56879.77% in 2021, then crashed by 3780.23% in 2025.
  • Gain Therapeutics' Operating Expenses (Quarter) stood at $3.3 million in 2021, then surged by 40.26% to $4.6 million in 2022, then fell by 3.38% to $4.4 million in 2023, then dropped by 24.42% to $3.3 million in 2024, then skyrocketed by 43.67% to $4.8 million in 2025.
  • Its last three reported values are $4.8 million in Q3 2025, $5.1 million for Q2 2025, and $4.4 million during Q1 2025.